nodes	percent_of_prediction	percent_of_DWPC	metapath
Dextroamphetamine—SLC6A3—Gilles de la Tourette syndrome	0.874	1	CbGaD
Dextroamphetamine—SLC6A2—autonomic nervous system—Gilles de la Tourette syndrome	0.00913	0.198	CbGeAlD
Dextroamphetamine—TAAR1—nervous system—Gilles de la Tourette syndrome	0.00557	0.121	CbGeAlD
Dextroamphetamine—TAAR1—central nervous system—Gilles de la Tourette syndrome	0.00536	0.116	CbGeAlD
Dextroamphetamine—TAAR1—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.00409	0.0557	CbGpPWpGaD
Dextroamphetamine—TAAR1—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.00397	0.0541	CbGpPWpGaD
Dextroamphetamine—TAAR1—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0037	0.0504	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Nicotine Activity on Dopaminergic Neurons—DRD3—Gilles de la Tourette syndrome	0.0034	0.0464	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Na+/Cl- dependent neurotransmitter transporters—SLC6A3—Gilles de la Tourette syndrome	0.00339	0.0462	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Nicotine Activity on Dopaminergic Neurons—DRD4—Gilles de la Tourette syndrome	0.0033	0.045	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Nicotine Activity on Dopaminergic Neurons—DRD2—Gilles de la Tourette syndrome	0.00308	0.0419	CbGpPWpGaD
Dextroamphetamine—TAAR1—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00259	0.0353	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Amine compound SLC transporters—SLC6A3—Gilles de la Tourette syndrome	0.00235	0.0321	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Dopaminergic Neurogenesis—SLC6A3—Gilles de la Tourette syndrome	0.00235	0.0321	CbGpPWpGaD
Dextroamphetamine—SLC18A2—midbrain—Gilles de la Tourette syndrome	0.0023	0.0498	CbGeAlD
Dextroamphetamine—SLC6A2—Na+/Cl- dependent neurotransmitter transporters—SLC6A3—Gilles de la Tourette syndrome	0.00228	0.0311	CbGpPWpGaD
Dextroamphetamine—ADRA1B—nervous system—Gilles de la Tourette syndrome	0.00191	0.0414	CbGeAlD
Dextroamphetamine—SLC18A2—nervous system—Gilles de la Tourette syndrome	0.00189	0.041	CbGeAlD
Dextroamphetamine—ADRA1B—central nervous system—Gilles de la Tourette syndrome	0.00184	0.0398	CbGeAlD
Dextroamphetamine—SLC18A2—central nervous system—Gilles de la Tourette syndrome	0.00182	0.0394	CbGeAlD
Dextroamphetamine—SLC6A3—midbrain—Gilles de la Tourette syndrome	0.00174	0.0377	CbGeAlD
Dextroamphetamine—SLC6A2—Amine compound SLC transporters—SLC6A3—Gilles de la Tourette syndrome	0.00158	0.0216	CbGpPWpGaD
Dextroamphetamine—Diethylpropion—SLC6A3—Gilles de la Tourette syndrome	0.00151	0.221	CrCbGaD
Dextroamphetamine—SLC6A2—Monoamine Transport—SLC6A3—Gilles de la Tourette syndrome	0.0015	0.0205	CbGpPWpGaD
Dextroamphetamine—ADRA1B—brain—Gilles de la Tourette syndrome	0.00146	0.0316	CbGeAlD
Dextroamphetamine—SLC18A2—brain—Gilles de la Tourette syndrome	0.00145	0.0313	CbGeAlD
Dextroamphetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.00144	0.0197	CbGpPWpGaD
Dextroamphetamine—SLC6A3—nervous system—Gilles de la Tourette syndrome	0.00143	0.031	CbGeAlD
Dextroamphetamine—SLC6A3—central nervous system—Gilles de la Tourette syndrome	0.00138	0.0298	CbGeAlD
Dextroamphetamine—ADRA1A—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.00128	0.0175	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.00123	0.0168	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.00119	0.0163	CbGpPWpGaD
Dextroamphetamine—SLC6A2—nervous system—Gilles de la Tourette syndrome	0.00115	0.025	CbGeAlD
Dextroamphetamine—Lisdexamfetamine—SLC6A3—Gilles de la Tourette syndrome	0.00115	0.168	CrCbGaD
Dextroamphetamine—ADRA1B—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.00111	0.0152	CbGpPWpGaD
Dextroamphetamine—SLC6A2—central nervous system—Gilles de la Tourette syndrome	0.00111	0.0241	CbGeAlD
Dextroamphetamine—SLC6A3—brain—Gilles de la Tourette syndrome	0.00109	0.0237	CbGeAlD
Dextroamphetamine—ADRA1A—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.00109	0.0149	CbGpPWpGaD
Dextroamphetamine—ADRA1A—nervous system—Gilles de la Tourette syndrome	0.00107	0.0232	CbGeAlD
Dextroamphetamine—ADRA1A—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.00106	0.0145	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.00103	0.0141	CbGpPWpGaD
Dextroamphetamine—ADRA1A—central nervous system—Gilles de la Tourette syndrome	0.00103	0.0224	CbGeAlD
Dextroamphetamine—ADRA1B—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.001	0.0137	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.000988	0.0135	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.000935	0.0128	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—Gilles de la Tourette syndrome	0.00092	0.0125	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.000918	0.0125	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.000891	0.0122	CbGpPWpGaD
Dextroamphetamine—SLC6A2—brain—Gilles de la Tourette syndrome	0.000882	0.0191	CbGeAlD
Dextroamphetamine—ADRA1A—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.00083	0.0113	CbGpPWpGaD
Dextroamphetamine—ADRA1A—brain—Gilles de la Tourette syndrome	0.00082	0.0178	CbGeAlD
Dextroamphetamine—Phenylpropanolamine—SLC6A3—Gilles de la Tourette syndrome	0.000805	0.118	CrCbGaD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000804	0.011	CbGpPWpGaD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00078	0.0106	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.000779	0.0106	CbGpPWpGaD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000727	0.00991	CbGpPWpGaD
Dextroamphetamine—Phentermine—SLC6A3—Gilles de la Tourette syndrome	0.000717	0.105	CrCbGaD
Dextroamphetamine—ADRA1A—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.000692	0.00944	CbGpPWpGaD
Dextroamphetamine—Pseudoephedrine—SLC6A3—Gilles de la Tourette syndrome	0.00068	0.0994	CrCbGaD
Dextroamphetamine—ADRA1B—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.000655	0.00893	CbGpPWpGaD
Dextroamphetamine—CYP2D6—nervous system—Gilles de la Tourette syndrome	0.000632	0.0137	CbGeAlD
Dextroamphetamine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—Gilles de la Tourette syndrome	0.000619	0.00844	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000612	0.00835	CbGpPWpGaD
Dextroamphetamine—CYP2D6—central nervous system—Gilles de la Tourette syndrome	0.000609	0.0132	CbGeAlD
Dextroamphetamine—TAAR1—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000594	0.0081	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.000582	0.00793	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000554	0.00755	CbGpPWpGaD
Dextroamphetamine—Amphetamine—SLC6A3—Gilles de la Tourette syndrome	0.000552	0.0806	CrCbGaD
Dextroamphetamine—SLC18A2—Transmission across Chemical Synapses—SLC6A3—Gilles de la Tourette syndrome	0.000516	0.00703	CbGpPWpGaD
Dextroamphetamine—Methamphetamine—SLC6A3—Gilles de la Tourette syndrome	0.000511	0.0747	CrCbGaD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000509	0.00694	CbGpPWpGaD
Dextroamphetamine—Benzphetamine—SLC6A3—Gilles de la Tourette syndrome	0.000507	0.0741	CrCbGaD
Dextroamphetamine—CYP2D6—brain—Gilles de la Tourette syndrome	0.000483	0.0105	CbGeAlD
Dextroamphetamine—SLC6A2—NRF2 pathway—SLC6A3—Gilles de la Tourette syndrome	0.000446	0.00609	CbGpPWpGaD
Dextroamphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	0.000418	0.0057	CbGpPWpGaD
Dextroamphetamine—Amphetamine—DRD2—Gilles de la Tourette syndrome	0.00041	0.0599	CrCbGaD
Dextroamphetamine—SLC18A2—Neuronal System—SLC6A3—Gilles de la Tourette syndrome	0.000395	0.00539	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000388	0.00529	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000346	0.00472	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000336	0.00458	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000314	0.00428	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000313	0.00427	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000305	0.00416	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000284	0.00387	CbGpPWpGaD
Dextroamphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	0.000281	0.00384	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000237	0.00324	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00023	0.00314	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000219	0.00299	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000215	0.00293	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.000212	0.0029	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000211	0.00288	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000205	0.00279	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000203	0.00277	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000199	0.00271	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000197	0.00269	CbGpPWpGaD
Dextroamphetamine—ADRA1B—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.000194	0.00265	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000191	0.0026	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000186	0.00253	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000184	0.00251	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000181	0.00246	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00018	0.00246	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000175	0.00239	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.000174	0.00237	CbGpPWpGaD
Dextroamphetamine—ADRA1A—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.000173	0.00236	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000168	0.00229	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000163	0.00223	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000155	0.00211	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.000155	0.00211	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00015	0.00205	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00015	0.00205	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.000143	0.00195	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00014	0.00191	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000138	0.00188	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000134	0.00182	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000134	0.00182	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000129	0.00176	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000124	0.0017	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000118	0.0016	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000114	0.00156	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	9.81e-05	0.00134	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	8.75e-05	0.00119	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	8.71e-05	0.00119	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	8.5e-05	0.00116	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—HDC—Gilles de la Tourette syndrome	7.98e-05	0.00109	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	7.95e-05	0.00108	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	7.91e-05	0.00108	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	7.77e-05	0.00106	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	7.71e-05	0.00105	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	7.55e-05	0.00103	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	7.19e-05	0.00098	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	7.06e-05	0.000963	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	7.03e-05	0.000959	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	6.85e-05	0.000935	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	6.38e-05	0.000871	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	5.54e-05	0.000756	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	5.03e-05	0.000686	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	4.92e-05	0.000671	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	4.69e-05	0.00064	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	4.56e-05	0.000622	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	4.47e-05	0.00061	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	4.25e-05	0.000579	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	4.17e-05	0.000569	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	4.05e-05	0.000552	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	3.77e-05	0.000514	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	2.97e-05	0.000406	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	2.64e-05	0.00036	CbGpPWpGaD
